According to an AstraZeneca representative, the AZD1222 vaccine contains the genetic material of the SARS-CoV-2 virus spike protein, and the recent mutations in the virus do not affect the structure of the spike protein. Drug companies are rushing to test their COVID-19 vaccines against the new highly contagious variant of the virus spreading in Britain. Vaccination with AZD1222 helps the immune system recognize various parts of the spike protein, enabling it to eliminate the virus upon exposure. The B.1.1.7 lineage mutation, which is up to 70% more infectious and concerning for children, has caused turmoil in Britain, leading to travel bans and trade disruptions with Europe. The AstraZeneca-Oxford vaccine is seen as important for countries with lower incomes and hot climates because it is affordable, can be easily transported, and can be stored for long periods at regular refrigerator temperatures. Recent data from AstraZeneca's trials in the UK and Brazil showed varying efficacy rates, with a higher efficacy rate for a smaller sub-group given a half dose followed by a full dose. India is expected to approve the vaccine for emergency use by next week.